Retatrutide Dosing Guide: What Clinical Trials Tell Us

Medically reviewed by Dr. Sarah Chen, PharmD, BCPS

Understanding retatrutide's dosing protocol is important for healthcare providers and patients. This article reviews the dosing schedules used in clinical trials, the rationale for dose escalation, and how different doses affect efficacy and tolerability.

Retatrutide Dosing in Clinical Trials

Retatrutide is administered as a once-weekly subcutaneous injection, similar to other incretin-based therapies like semaglutide and tirzepatide. The dosing protocols used in clinical trials provide important insights into how the drug will likely be prescribed if approved. For a deeper dive into this area, see how to reconstitute and inject peptides.

Important disclaimer: Retatrutide is an investigational drug that has not been approved by the FDA or any regulatory agency. The dosing information below is based on clinical trial protocols and is provided for educational purposes only. Do not attempt to self-administer retatrutide.

Dose Ranges Studied

Clinical trials have evaluated retatrutide across a wide dose range:

Phase 1b Trial Doses [1]

0.5 mg once weekly

1.5 mg once weekly

3.0 mg once weekly

4.5 mg once weekly

6.0 mg once weekly

8.0 mg once weekly

12.0 mg once weekly

Phase 2 Obesity Trial Doses [2]

1 mg (maintenance dose)

4 mg (maintenance dose)

8 mg (maintenance dose)

12 mg (maintenance dose)

Phase 2 Diabetes Trial Doses [3]

0.5 mg (maintenance dose)

4 mg (two different escalation regimens)

8 mg (maintenance dose)

12 mg (maintenance dose)

---

> Interested in starting a supervised protocol? Telegenix offers telehealth peptide and TRT programs with ongoing lab monitoring and provider support. Book your free consultation today.

---

Dose Escalation Protocol

A critical aspect of retatrutide dosing is the gradual dose escalation approach. Rather than starting at the target maintenance dose, patients begin at a low dose and increase incrementally over several weeks. This approach significantly reduces the incidence and severity of gastrointestinal side effects.

Typical Escalation Schedule (Phase 2 Obesity Trial)

For the 12 mg target dose, the escalation followed approximately this pattern:

Weeks 1-4: Starting dose (e.g., 2 mg)

Weeks 5-8: Intermediate dose (e.g., 4 mg)

Weeks 9-12: Higher intermediate dose (e.g., 8 mg)

Weeks 13+: Target maintenance dose (12 mg)

The exact escalation schedule varied between trials and dose groups, but the principle of gradual titration was consistent across all studies.

Why Dose Escalation Matters

Starting at a low dose and gradually increasing allows the body to adapt to the drug's effects, particularly:

GI tolerance: The nausea, vomiting, and diarrhea associated with GLP-1 agonism are most pronounced when treatment begins or doses increase; gradual titration minimizes these effects

Metabolic adjustment: The body needs time to adapt to changes in appetite, gastric emptying, and energy metabolism

Safety monitoring: Gradual escalation allows clinicians to monitor for adverse effects at each dose level before increasing

Dose-Response Relationships

Weight Loss

The relationship between retatrutide dose and weight loss is clearly dose-dependent:

1 mg: ~8.7% weight loss

4 mg: ~17.1% weight loss

8 mg: ~22.8% weight loss

12 mg: ~24.2% weight loss

The incremental benefit diminishes at higher doses (the jump from 8 mg to 12 mg is smaller than from 4 mg to 8 mg), suggesting a flattening dose-response curve.

A1C Reduction

Interestingly, the glycemic dose-response is not strictly linear:

8 mg: ~1.99% A1C reduction

12 mg: ~1.91% A1C reduction

The slightly lower A1C reduction at 12 mg compared to 8 mg may reflect increased glucagon receptor activation at the highest dose, which partially offsets glucose-lowering effects.

Side Effects

Adverse events are clearly dose-dependent, with higher doses associated with more GI side effects and higher discontinuation rates. The 12 mg dose had a 16% discontinuation rate compared to 6% at 8 mg.

Optimal Dose Selection

The optimal dose will likely depend on the treatment goal and individual patient tolerance:

For maximum weight loss: 12 mg appears optimal, though 8 mg provides nearly as much weight loss with better tolerability

For type 2 diabetes: 8 mg may offer the best balance of glycemic control and tolerability

For liver fat reduction: Higher doses (8-12 mg) showed the most dramatic liver fat reductions

For patients with GI sensitivity: Lower doses (4 mg) still provide clinically meaningful benefits with fewer side effects

Administration

Injection Technique

Route: Subcutaneous (under the skin)

Frequency: Once weekly, on the same day each week

Injection sites: Abdomen, thigh, or upper arm (rotating sites)

Timing: Can be administered at any time of day, with or without meals

Pharmacokinetics

The Phase 1b trial established that retatrutide has pharmacokinetics suitable for once-weekly dosing, with a half-life that maintains therapeutic drug levels throughout the dosing interval [1].

What to Expect If Approved

If retatrutide receives FDA approval, the prescribing information will likely include:

A recommended starting dose with a defined escalation schedule

Multiple maintenance dose options to allow individualized treatment

Guidance on dose adjustment based on tolerability

Specific instructions for missed doses

> Related Comparison: Ozempic vs Mounjaro: Complete Comparison

References

Urva S, et al. "LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b trial." The Lancet. 2022;400(10366):1869-1881. PubMed: 36354040

Jastreboff AM, et al. "Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial." NEJM. 2023;389(6):514-526. PubMed: 37366315

Rosenstock J, et al. "Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes." The Lancet. 2023;402(10401):529-544. PubMed: 37385280

---

> Take the next step in your optimization journey. If you're ready to move beyond research and into a supervised protocol, Telegenix offers physician-guided peptide and TRT programs with full lab support. Book a free consultation today.

---